Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants

Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants

Publication: Clin Pharmacol Drug Dev

Sphingosine‐1‐phosphate (S1P) binding to the S1P‐1 receptor (S1P1R) controls the egress of lymphocytes from lymphoid organs and targets modulation of immune responses in

In silico pharmacokinetic study of vancomycin using PBPK modeling and therapeutic drug monitoring

In silico pharmacokinetic study of vancomycin using PBPK modeling and therapeutic drug monitoring

Publication: Curr Drug Metab

Vancomycin has been in clinical use for nearly 50 years and remains as the first line treatment option for Gram-positive infections..

Patient-centric design for peptide delivery: Trends in routes of administration and advancement in drug delivery technologies

Patient-centric design for peptide delivery: Trends in routes of administration and advancement in drug delivery technologies

Publication: Medicine in Drug Discovery
Software: GastroPlus®

Utilizing peptides as therapeutic agents is considered an attractive approach for the treatment of various diseases due to their high...

Computational Modeling and Pharmacokinetics/ADMET Study of Some Arylpiperazine Derivatives as Novel Antipsychotic Agents Targeting Depression

Computational Modeling and Pharmacokinetics/ADMET Study of Some Arylpiperazine Derivatives as Novel Antipsychotic Agents Targeting Depression

Publication: Chemistry Africa
Software: ADMET Predictor®

This study focuses on Quantitative structure–activity relationship (QSAR) and in silico pharmacokinetics/ADMET predictions to investigate the structural...

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia.

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia.

Publication: J Clin Pharmacol

Quizartinib is an FMS-like tyrosine kinase 3 (FLT3) inhibitor that has shown robust clinical activity in patients with FLT3-internal tandem duplication-mutated relapsed/refractory acute myeloid leukemia (AML).

Reliance: a smarter way of regulating medical products – The IPRP survey

Reliance: a smarter way of regulating medical products – The IPRP survey

Publication: Expert Rev Clin Pharmacol
Division: PBPK

A survey was conducted among national regulatory authorities' members of the International Pharmaceutical Regulators Programme (IPRP) to collect and share experiences of reliance approaches.

Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development

Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development

Publication: Drug Discov Today
Software: GastroPlus®

Drug-delivery technologies for modified drug release have been in existence for decades, but their utilization has been largely limited..

Insights of Tris(2-pyridylmethyl)amine as anti-tumor agent for osteosarcoma: experimental and in silico studies

Insights of Tris(2-pyridylmethyl)amine as anti-tumor agent for osteosarcoma: experimental and in silico studies

Publication: Journal of Molecular Structure
Software: ADMET Predictor®

Osteosarcoma (OS) is a malignant bone tumor and its occurrence is associated with high levels of microRNAs (miRNAs) and critical protein involved on intracellular signaling pathways.